Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flu Vaccine Supply Is Focus Of House Govt. Reform Hearing Feb. 10

This article was originally published in The Pink Sheet Daily

Executive Summary

CDC is expected to discuss efforts to combat local-level supply-and-demand mismatches. Sanofi Pasteur’s role in distributing federal emergency reserve doses and Chiron’s uncertain status for the 2005-2006 flu season are among the likely discussion topics.

You may also be interested in...



Chiron’s Fluvirin Distribution Contracts Under Discussion

The company and its vaccine distributors will determine whether contracts for 2004 will be extended for the next flu season given uncertainty over whether Fluvirin will be available. Additional clarity on Fluvirin supply is expected in “early spring.”

House Appropriations Subcommittee Plans FDA Hearing July 26

Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.

Second Quarter Earnings Season Heats Up

Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel